17 results found.

Spondylitis, Ankylosing Clinical Trial using Placebo; BI 655066

Boehringer Ingelheim - Recruiting 18 years to 70 years.
- A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis..
Placebo; BI 655066

Spondylitis, Ankylosing Clinical Trial using Secukinumab

Novartis - Recruiting 18 years or older.
- An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis.
Secukinumab

Ankylosing Spondylitis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study.

Ankylosing Spondylitis Clinical Trial using AIN457; Placebo

Novartis - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled Phase III Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Ankylosing Spondylitis.
AIN457; Placebo

Ankylosing Spondylitis Clinical Trial using Tofacitinib 2 mg; Tofacitinib 5 mg; Tofacitinib 10 mg; Placebo

Pfizer - Recruiting 18 years or older.
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (AS).
Tofacitinib 2 mg; Tofacitinib 5 mg; Tofacitinib 10 mg; Placebo

Ankylosing Spondylitis Clinical Trial using Golimumab

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012.
Golimumab

Spondylitis, Ankylosing Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Progression of Spinal Fusion in Ankylosing Spondylitis.

Spondylitis, Ankylosing Clinical Trial using Secukinumab; Placebo secukinumab

Novartis - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis.
Secukinumab; Placebo secukinumab

Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Eryt Clinical Trial using Interleukin 2

Assistance Publique - H“pitaux de Paris - Recruiting 18 years or older.
- Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach.
Interleukin 2

Rheumatoid Arthritis, Ankylosing Spondylitis, Lupus Erythematosus Clinical Trial using Employment and Arthritis: Making it Work

University of British Columbia - Recruiting 18 years to 59 years.
- Employment and Arthritis: Making it Work: A Randomized Controlled Trial Evaluating an On-line Program to Help People With Inflammatory Arthritis Remain Employed.
Employment and Arthritis: Making it Work

Spondylitis, Ankylosing Clinical Trial using Part I - etoricoxib 60 mg; Part I - etoricoxib 90 mg; Part I- naproxen 1000 mg; Part I - Placebo to naproxen 500 mg; Part II- etoricoxib 60 mg; Part II- etoricoxib 90 mg; Part II- naproxen 1000 mg; Part I - Placebo to etoricoxib 60 mg; Part I - Placebo to etoricoxib 90 mg; Part II- Placebo to etoricoxib 60 mg; Part II - Placebo to etoricoxib 90 mg; Part II- Placebo to naproxen 500 mg

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis.
Part I - etoricoxib 60 mg; Part I - etoricoxib 90 mg; Part I- naproxen 1000 mg; Part I - Placebo to naproxen 500 mg; Part II- etoricoxib 60 mg; Part II- etoricoxib 90 mg; Part II- naproxen 1000 mg; Part I - Placebo to etoricoxib 60 mg; Part I - Placebo to etoricoxib 90 mg; Part II- Placebo to etoricoxib 60 mg; Part II - Placebo to etoricoxib 90 mg; Part II- Placebo to naproxen 500 mg

Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Clinical Trial using Blood draw from mother; Blood draw from infant; Blood draw from umbilical cord; Certolizumab Pegol

UCB, Inc. - Recruiting 18 years or older.
- A Multicenter Postmarketing Study to Evaluate the Placental Transfer of Certolizumab Pegol in Pregnant Women Receiving Treatment With Cimziar (Certolizumab Pegol) Phase 1b (Clinical Pharmacology).
Blood draw from mother; Blood draw from infant; Blood draw from umbilical cord; Certolizumab Pegol

Ankylosing Spondylitis Clinical Trial using no intervention

Pfizer - Recruiting 18 years to 75 years.
- Assial - Anti Tnf Treatment in Ankylosing Spondylitis: an Observational Cohort Study in Italy.
no intervention

Arthritis, Rheumatoid, Spondylitis, Ankylosing, or Arthritis, Pso Clinical Trial

Janssen Inc. - Recruiting N/A or older.
- BioTRAC (BIOLOGIC TREATMENT REGISTRY ACROSS CANADA) Rheumatology (Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis).

Ankylosing Spondylitis Clinical Trial

AbbVie - Recruiting 16 years or older.
- Special Investigation (All Cases Investigation in Patients With Ankylosing Spondylitis).

Ankylosing Spondylitis, or Psoriatic Arthritis Clinical Trial

AbbVie - Recruiting 18 years to 50 years.
- Observational Study in AS and PsA Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium.

Rheumatoid Arthritis, Ankylosing Spondylitis, or Psoriatic Arthri Clinical Trial

AbbVie - Recruiting 18 years or older.
- Assessment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patient`s Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice.